Marc De Backer

736 total citations
33 papers, 552 citations indexed

About

Marc De Backer is a scholar working on Pediatrics, Perinatology and Child Health, Psychiatry and Mental health and Oncology. According to data from OpenAlex, Marc De Backer has authored 33 papers receiving a total of 552 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pediatrics, Perinatology and Child Health, 26 papers in Psychiatry and Mental health and 7 papers in Oncology. Recurrent topics in Marc De Backer's work include Epilepsy research and treatment (26 papers), Pharmacological Effects and Toxicity Studies (26 papers) and Drug Transport and Resistance Mechanisms (7 papers). Marc De Backer is often cited by papers focused on Epilepsy research and treatment (26 papers), Pharmacological Effects and Toxicity Studies (26 papers) and Drug Transport and Resistance Mechanisms (7 papers). Marc De Backer collaborates with scholars based in Belgium, United States and Germany. Marc De Backer's co-authors include Pamela Doty, Ting Li, David Hébert, Jouko Isojärvi, Kiyohito Terada, Melissa Brock, Konrad J. Werhahn, Michel Baulac, Felix Rosenow and Manuel Toledo and has published in prestigious journals such as Neurology, The Journal of Physical Chemistry and The Lancet Neurology.

In The Last Decade

Marc De Backer

28 papers receiving 539 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marc De Backer Belgium	12	460	437	179	112	60	33	552
Pascal Edrich United States	9	377 0.8×	343 0.8×	160 0.9×	65 0.6×	19 0.3×	13	449
Takuji Nishida Japan	12	270 0.6×	208 0.5×	105 0.6×	33 0.3×	39 0.7×	45	419
Daniela Mamoli Italy	12	274 0.6×	324 0.7×	57 0.3×	53 0.5×	16 0.3×	16	467
C. Arrigo Belgium	9	348 0.8×	315 0.7×	133 0.7×	84 0.8×	5 0.1×	14	486
Karen Booth McCormick United States	8	203 0.4×	246 0.6×	61 0.3×	36 0.3×	26 0.4×	11	409
D Beaumont France	7	244 0.5×	183 0.4×	126 0.7×	36 0.3×	29 0.5×	10	321
Chih‐Hsiang Lin Taiwan	11	176 0.4×	160 0.4×	45 0.3×	30 0.3×	12 0.2×	25	314
Shih Hui Lim Singapore	9	145 0.3×	122 0.3×	37 0.2×	58 0.5×	26 0.4×	18	333
T. Goggin Ireland	8	355 0.8×	386 0.9×	82 0.5×	43 0.4×	9 0.1×	10	464
George Belendiuk United States	9	84 0.2×	75 0.2×	45 0.3×	34 0.3×	59 1.0×	12	601

Countries citing papers authored by Marc De Backer

Since Specialization

Citations

This map shows the geographic impact of Marc De Backer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc De Backer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc De Backer more than expected).

Fields of papers citing papers by Marc De Backer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc De Backer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc De Backer. The network helps show where Marc De Backer may publish in the future.

Co-authorship network of co-authors of Marc De Backer

This figure shows the co-authorship network connecting the top 25 collaborators of Marc De Backer. A scholar is included among the top collaborators of Marc De Backer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc De Backer. Marc De Backer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vlaev, Ivo, Ashwin Pinto, Channa Hewamadduma, et al.. (2025). What Patients Don’t Say and Physicians Don’t Ask: A Needs Assessment in Myasthenia Gravis Integrating Patient and Healthcare Professional Perspectives. Neurology and Therapy. 14(4). 1419–1438.

Steinhoff, Bernhard J., Jakob Christensen, Colin P. Doherty, et al.. (2020). Effectiveness and tolerability of adjunctive brivaracetam in patients with focal seizures: Second interim analysis of 6-month data from a prospective observational study in Europe. Epilepsy Research. 165. 106329–106329. 13 indexed citations

Schmitz, Bettina, et al.. (2019). Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial. Epilepsy Research. 159. 106220–106220. 12 indexed citations

Weber, Yvonne, Gerhard Luef, Lars Joeres, et al.. (2019). Changes in drug load during lacosamide combination therapy: A noninterventional, observational study in German and Austrian clinical practice. Epilepsia Open. 4(3). 409–419. 7 indexed citations

Giráldez, Beatriz G., Manuel Toledo, Gerrit‐Jan de Haan, et al.. (2017). Effectiveness of lacosamide monotherapy in clinical practice: a retrospective chart review in patients with focal seizures (P5.230). Neurology. 88(16_supplement). 1 indexed citations

Toledo, Manuel, Michel Baulac, Felix Rosenow, et al.. (2017). Efficacy of lacosamide monotherapy in patients with newly diagnosed epilepsy stratified by baseline disease severity: sub-analysis of data from a prospective non-inferiority trial versus controlled-release carbamazepine (P5.227). Neurology. 88(16_supplement).

Rosenow, Felix, Manuel Toledo, Michel Baulac, et al.. (2017). Efficacy and tolerability of lacosamide monotherapy in elderly patients with newly diagnosed epilepsy: subgroup analysis of a non-inferiority trial versus controlled-release carbamazepine (P5.232). Neurology. 88(16_supplement). 1 indexed citations

Schmitz, Bettina, Mark R. Newton, Svetlana Dimova, et al.. (2017). Tolerability and efficacy of lacosamide monotherapy in patients with newly-diagnosed epilepsy and psychiatric comorbidities: Post hoc analysis of a prospective, randomized, double-blind trial (P5.229). Neurology. 88(16_supplement). 2 indexed citations

Steinhoff, Bernhard J., et al.. (2016). A long-term noninterventional safety study of adjunctive lacosamide therapy in patients with epilepsy and uncontrolled partial-onset seizures. Epilepsy & Behavior. 58. 35–43. 22 indexed citations

10.

Elger, Christian E., Michael Rademacher, Christian Brandt, et al.. (2016). Changes in hormone and lipid levels in male patients with focal seizures when switched from carbamazepine to lacosamide as adjunctive treatment to levetiracetam: A small phase IIIb, prospective, multicenter, open-label trial. Epilepsy & Behavior. 62. 1–5. 14 indexed citations

11.

Meador, Kimford J., David W. Loring, Alan Boyd, et al.. (2016). Randomized double-blind comparison of cognitive and EEG effects of lacosamide and carbamazepine. Epilepsy & Behavior. 62. 267–275. 23 indexed citations

12.

Baulac, Michel, Felix Rosenow, Manuel Toledo, et al.. (2016). Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. The Lancet Neurology. 16(1). 43–54. 119 indexed citations

13.

Escartín, Antonio, Frank Tennigkeit, Peter Dedeken, et al.. (2015). Safety and Effectiveness of Lacosamide as a First Add-on (FAO) or Later Add-on (LAO) Treatment of Partial-onset Seizures (POS) in Adults: an Open-label Trial (P4.262). Neurology. 84(14_supplement). 1 indexed citations

14.

Escartín, Antonio, Frank Tennigkeit, Simon Borghs, et al.. (2015). Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial. Seizure. 31. 72–79. 47 indexed citations

15.

Baulac, Michel, et al.. (2015). Cross-titration of lacosamide with a sodium channel blocker in patients with partial onset seizures on a stable dose regimen of levetiracetam: safety and efficacy (P1.240). Neurology. 84(14_supplement). 1 indexed citations

16.

Dimova, Svetlana, et al.. (2014). Effect of Adjunctive Lacosamide on Complex Partial Seizures and Partial Seizures with Secondary Generalization in Adults: Pooled Analysis of Three Open-label Extension Trials (P3.269). Neurology. 82(10_supplement). 1 indexed citations

17.

D’Cruz, O’Neill, et al.. (2013). Long-Term Treatment of Partial-Onset Seizures in Adults Exposed Only to Approved Lacosamide Doses: Pooled Analysis of Three Open-Label Extension Studies (P07.170). Neurology. 80(7_supplement). 1 indexed citations

18.

Hébert, David, et al.. (2010). A Pooled Analysis of Lacosamide Clinical Trial Data Grouped by Mechanism of Action of Concomitant Antiepileptic Drugs. CNS Drugs. 24(12). 1055–1068. 159 indexed citations

19.

Backer, Marc De, Marie‐Anne Morren, Hugo Boonen, et al.. (2008). Belgian Observational Drug Utilization Study of Pimecrolimus Cream 1% in Routine Daily Practice in Atopic Dermatitis. Dermatology. 217(2). 156–163. 7 indexed citations

20.

Wallemacq, Pierre, Raymond Reding, Étienne Sokal, et al.. (1997). Clinical pharmacokinetics of Neoral in pediatric recipients of primary liver transplants. Transplant International. 10(6). 466–470. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact